THE ISRAELI GENETIC CJD
E200K BIOBANK

A National Longitudinal Research Resource

Alice Anane[1] · Tal Anane[1] · Shirel Ostrovski[2] · Adelina Ovcharenko[3]
Aldana D. Gojanovich[4] · Gustavo Mostoslavsky[4] · Victor Novack[2]

[1]CJD Foundation Israel [2]Soroka-Clalit HMO [3]MIDGAM [4]CReM,Boston University (genetic testing)

360 PARTICIPANTS | **521** VISITS | **5** CONVERSIONS | **700+** E200K FAMILIES IN CONTACT

SCIENTIFIC RATIONALE & STUDY OBJECTIVES

Longitudinal PRNP E200K family cohort for biomarker discovery, penetrance, disease modifiers and trial readiness.

BIOSPECIMENS & RESEARCH DATA


Blood and non-blood samples linked to clinical and multigenerational family data.

COHORT COMPOSITION N = 360



■ 37 SYMPTOMATIC | ■ 84 ASYMPTOMATIC CARRIERS | ■ 112 NON-CARRIERS | ■ 127 UNKNOWN

AGE DISTRIBUTION / GENOTYPE GROUPS - ASYMPTOMATIC



Age at last recorded sample collection

5 conversions: longitudinal samples before and after symptom onset

SELECTED PUBLICATIONS

National CJD Research Biobank
Anane A, et al. Orphanet J Rare Diseases 2025; 20:170

Age-Dependent Penetrance of CJD in PRNP E200K Carriers
Dayan R, Anane A, et al. Neurology Accepted (2026).

RESEARCH COLLABORATIONS

- 20 researchers with Israeli Supreme Helsinki Committee approval
- PRIONOMICS • PrionAtRisk • AID-PRION

PLANNED CJDbio DATA PLATFORM

In development: integration of longitudinal clinical, genomic and multi-omics data.